APS.TO Stock - Aptose Biosciences Inc.
Unlock GoAI Insights for APS.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-474,545 | $-507,079 | $-616,527 | $-646,435 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-26,257,000 | $-52,356,000 | $-42,602,000 | $-65,447,000 | $-55,768,000 |
| Net Income | $-25,430,000 | $-51,207,000 | $-41,823,000 | $-65,354,000 | $-55,238,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-7.58 | $-6.80 | $-11.01 | $-9.30 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
APS.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-2.72 | $-2.80 | -3.1% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-3.73 | $-3.76 | -0.8% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-2.49 | $-2.61 | -4.8% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-1.68 | $-1.34 | +20.2% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-1.19 | $-0.37 | +68.9% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.18 | $-0.43 | +63.6% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.74 | $-0.73 | +1.4% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-1.59 | $-1.44 | +9.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-2.05 | $-1.76 | +14.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-2.01 | $-2.27 | -12.9% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.11 | $-0.11 | 0.0% | = MET |
Q4 2022 | Nov 1, 2022 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-0.17 | $-0.27 | -58.8% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Latest News
Frequently Asked Questions about APS.TO
What is APS.TO's current stock price?
What is the analyst price target for APS.TO?
What sector is Aptose Biosciences Inc. in?
What is APS.TO's market cap?
Does APS.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to APS.TO for comparison